Navigation Links
The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone shows median survival of 35 months, nearly three years. The data are pooled from two large randomized controlled Phase III trials that enrolled more than 700 patients from nearly 100 clinical sites worldwide. These updated results were presented at the 11th International Myeloma Workshop in Kos, Greece.

"Here in Kos we are seeing what is truly a paradigm shift in treatment for multiple myeloma patients," said Greetje Goossens, EMP member and leader of the Belgium myeloma support group. "The experts here are saying that nearly three years of median over all survival for REVLIMID patients is the longest they have seen in myeloma to-date from large clinical trials."

This is the first major medical meeting since REVLIMID, an oral breakthrough therapy, was approved in Europe earlier this month for multiple myeloma patients. It has been approved for the past year in the United States. Previously it was reported that for newly diagnosed patients in a large randomized Phase III trial, REVLIMID with low dose dexamethasone demonstrated an unprecedented 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over. Investigators characterized this as the best one-year survival data they have seen in a large phase 3 study in myeloma.

"We are very excited about these data," said Dr. Rolf Pelzing of Germany, Vice-Chairperson, EMP. "There is no cure for myeloma, but from personal experience, I can say that the duration of survival and the quality of life is improving significantly for many of us as demonstrated by the powerful new data that were presented at the meeting in Kos."

Multiple myeloma is a rare form of cancer of plasma cells. It is the second most comm
'"/>




Page: 1 2

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

Post Your Comments:
(Date:11/20/2009)...Newswire-FirstCall/ -- Smith & Nephew ( SNN, L...ce the signing of a technology development contrac...t may lead to the creation of a fracture fixation ...the limbs of soldiers who sustain battlefield inju...ch Projects Agency (DARPA), the central research a...
(Date:11/19/2009)... BioCryst Pharmaceuticals...g of a public offering of 5,000,000 shares of its ...s proceeds of $48.75 million. All of the shares a...ive shelf registration statement previously filed ...ryst has also granted the underwriters a 30-day op...
(Date:11/19/2009)...9 /PRNewswire-Asia/ -- ScinoPharm, a leading globa...PIs), announced that its,Tainan facility has recei...SafeBridge(R) Consultants, Inc. The Certification ...n the safe handling of potent active,pharmaceutica...ratories and,production areas used for the manufac...
Breaking Medicine Technology:Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2CQ Forum on Biosimilar Biological Products Wed June 17 2009 12618 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 1Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 2Proteolix Inc Drug Candidate PR 957 Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 4591 3Coming Soon 3A Lung Cancer Spray 3F 48863 1Coming Soon 3A Lung Cancer Spray 3F 48863 2
...in Long-term PASI 75, Response and Marked Improve... Study Findings, BUENOS AI...s from an international, Phase 3 study showed that... severe plaque psoriasis receiving,two doses of us...nt,reduction in psoriasis at week 12, the primary ...
...es, Inc. (Nasdaq: RMTI ), a leading, innovative m...ialty pharmaceuticals focused on the end-,stage-re... has begun dosing,patients in its Phase IIb Dose-R...hate (SFP), the Company,s physiological iron-maint...n is a double-blind, multi-center,randomized, plac...
Other Medicine Technology:Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 2Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 3Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 4Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 5Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis 6Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 2Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 3Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study 4
(Date:11/20/2009)...l, November 20 Cardio Va....CVSLMEDICAL.COM , a leading,developer of advanced...d that,the company,s Board of Directors has decide...a and the Far East for its proprietary next-genera...oplasty (PCTA) procedures. , Cardio Vascu...
(Date:11/20/2009)...o formaldehyde used for embalming in the funeral i...death from myeloid leukemia, according to a new st...f the National Cancer Institute . , Previous stu...poietic malignancies and brain cancer in anatomist... of whom may have worked with formaldehyde. , ...
(Date:11/20/2009)... buying 90-day supply, study finds , , F...month supply of prescription drugs is up to one-th...ing to a new study. , U.S. researchers analyzed... 2000 and 2005, and found that patients who bought...y saved an average 29 percent in out-of-pocket cos...
(Date:11/20/2009)...ov. 20 Missouri state employees in...will now have the option to choose Mercy Health Pl... Missouri Consolidated Health Care Plan (MCHCP) an...h Central Missouri regions include the following c...llas, Douglas, Greene, Hickory, Howell, Jasper, La...
(Date:11/20/2009)... The Senate,s newly rel...Affordable Care Act") infringes on Americans, heal... Blevins, president of the Institute for Health Fr...ton, D.C. ,, The bill would (among many other ...ident to buy government-sanctioned health insuranc...
Breaking Medicine News(10 mins):Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Three-Month Supply Lowers Drug Costs 2Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Senate Mandatory Health-Insurance Bill Infringes on Choice and Privacy 2
...h, scientists have successfully converted human em...ope that in future, replacement cartilage could be...s and medical // problems, including sports injuri...rnal Tissue Engineering, involved growing human em...
...s are developing tests that can identify the begin...l signs of the disease emerge. The researche...at the annual meeting of the Society for Neuroscie... study groups, doctors could start using the tests...
...hat replaces some carbohydrates with either protei...blood pressure and cholesterol levels, resulting i... disease, // according to government-funded studie...otein-rich food, mostly from plant sources, or to ...
...t heart disease is ranked as the first most common... test called dobutamine stress echocardiography th...s in women. // The study has been conducted ...that can be categorized into two- traditional and ...
...be now detected by using a hand-held scope called ...Agency from the fund given by National Institute o... blue light that // is better than the conventiona... is achieved when oral cancer is treated in its ea...
...is patients in Britain can look forward to some re...vailable to them for the first time, following app...m Canada. // Patients in Britain will soon b...s yet to be licensed in the UK. The Home Office ha...
Other Medicine News:Health News:Another Potential Of Stem Cells Discovered: Used For Growing Cartilage 2Health News:Diagnosis of Alzheimer's years before clinical signs emerge 2Health News:A new study by John Hopkins University proposes formula for good health 2Health News:A new study by John Hopkins University proposes formula for good health 3Health News:A Simple Test To Detect Heart Disease In Women Can Be Lifesaving 2Health News:Relief For British MS Patients: Cannabis-Based Oral Spray 2
VACUETTE® Tube Holders
Safety Phlebotomy PROGUARD II Safety Needle Holder
Optima III 45 Noninsulated Duck-Bill Grasper, without ratchet
Optima III Noninsulated Stabilizing Grasper, with ratchet
Medicine Products: